Readmissions Sample Clauses

Readmissions. Definition: PACE participants re-admitted to an acute care hospital (excluding hospitalizations for diagnostic tests) in the last 30 days. 1. Total number of participants; 2. Total number of participants admitted to the hospital in the last 30 days; 3. Specific reason, including diagnosis, for participant’s admission; Frequency: Quarterly
AutoNDA by SimpleDocs
Readmissions. A readmission is defined to mean any subsequent admission to an acute care facility that occurs within the Episode Period. However, whether a Readmission is included in the contracted episode rate (and thus may not be separately billed) depends on: a) the facility where the patient is readmitted, and b) whether the readmission is considered to have been caused by or related to the Index Procedure (according to rules below).  Hospital and Physician Group agree that patients will be readmitted to Hospital except when: the patient requires emergency admission to a closer facility, the patient requires care that cannot be provided at Hospital, or the patient refuses to be readmitted to the Hospital.  A readmission at the Hospital is assumed to be related to the Index Procedure and is included in the episode price (may not be separately billed) if the readmission groups to one of the defined set of DRGs below.  175, 176—Pulmonary embolism  294, 295—Deep vein thrombophlebitis  463, 464, 465—Wnd debrid & skn grft, exc hand, for musculo-conn tiss dis  466, 467, 468—Revision of hip or knee replacement  485, 486, 487, 488, 489—Knee Procedures with and without pdx of Infection  539, 540, 541—Xxxxxxxxxxxxx  000, 000—Bone diseases & arthropathies  555, 556—Signs & symptoms of musculoskeletal system & conn tissue  559, 560, 561—Aftercare, musculoskeletal system & connective tissue  564, 565, 566—Other musculoskeletal sys & connective tissues diagnoses  602, 603—Xxxxxxxxxx  000, 000, 000, 000, 000—Post-operative or post-traumatic infections  870, 871, 872—Septicemia or severe sepsis (note: these DRGs are included only if septicemia is related to a septic joint or central line infection)  901, 902, 903—Wound debridements for injuries  919, 920, 921—Complications of treatment  939, 940, 941—O.R. procedure with diagnosis of other contact w health services  175, 176—Pulmonary embolism  294, 295—Deep vein thrombophlebitis  463, 464, 465—Wnd debrid & skn grft, exc hand, for musculo-conn tiss dis  466, 467, 468—Revision of hip or knee replacement  480, 481, 482—Hip & Femur procedures except major joint  533, 534—Xxxxxxxxx xx Xxxxx  000, 000—Fractures hip and pelvis  537,538—Sprains, strains, dislocation hip , pelvis, thigh  539, 540, 541—Xxxxxxxxxxxxx  000, 000—Bone diseases & arthropathies  555, 556—Signs & symptoms of musculoskeletal system & conn tissue  559, 560, 561—Aftercare, musculoskeletal system & connective tissue  564, 565, 566—Other mu...
Readmissions. For purposes of the Bundled Payment Program, a Readmission is defined to mean any subsequent admission to an acute care facility that occurs within the Episode Period. However, whether a Readmission is included in the contracted episode rate (and thus may not be separately billed) depends on: a) the facility where the patient is readmitted, and b) whether the readmission is considered to have been caused by or related to the Index Procedure (according to rules below). • Provider agrees that Covered Persons will be readmitted to the applicable hospital (i.e., the hospital participating under the Bundled Payment Program (the “Participating Hospital”)) except when: the Covered Person requires emergency admission to a closer facility, the Covered Person requires care that cannot be provided at the Participating Hospital, or the Covered Person refuses to be readmitted to the Participating Hospital. • A readmission at to the Participating Hospital is assumed to be related to the Index Procedure and is included in the episode price (may not be separately billed) if the readmission groups to one of the defined set of DRGs below. • 175, 176—Pulmonary embolism • 294, 295—Deep vein thrombophlebitis • 463, 464, 465—Wnd debrid & skn grft, exc hand, for musculo-conn tiss dis • 466, 467, 468—Revision of hip or knee replacement • 485, 486, 487, 488, 489—Knee Procedures with and without pdx of Infection • 539, 540, 541—Osteomyelitis • 553, 554—Bone diseases & arthropathies • 555, 556—Signs & symptoms of musculoskeletal system & conn tissue • 559, 560, 561—Aftercare, musculoskeletal system & connective tissue • 564, 565, 566—Other musculoskeletal sys & connective tissues diagnoses • 602, 603—Cellulitis • 856, 857, 858, 862, 863—Post-operative or post-traumatic infections • 870, 871, 872—Septicemia or severe sepsis (note: these DRGs are included only if septicemia is related to a septic joint or central line infection) • 901, 902, 903—Wound debridements for injuries • 919, 920, 921—Complications of treatment • 939, 940, 941—O.R. procedure with diagnosis of other contact w health services • 175, 176—Pulmonary embolism • 294, 295—Deep vein thrombophlebitis • 463, 464, 465—Wnd debrid & skn grft, exc hand, for musculo-conn tiss dis • 466, 467, 468—Revision of hip or knee replacement • 480, 481, 482—Hip & Femur procedures except major joint • 533, 534—Fractures of Femur • 535, 536—Fractures hip and pelvis • 537,538—Sprains, strains, dislocation hip , pelvis, thigh • 539, 540, 541...
Readmissions. HSAG desires to access the Hospital’s data held by NHSN (“Data Stewards”) and electronic health record (EHR) data, when available and applicable, to permit its use to measure and track HQIC performance between September 18, 2020 and September 17, 2024.
Readmissions. IHI, State of Michigan (Readmission data sent to MI-lA/MPRO as part of the IHI STAAR project)
Readmissions. Mercy Hospital has begun a multi-year effort to address readmissions for heart failure. With its partners at Metropolitan Heart and Vascular Institute, the Mercy Heart Failure Clinic helps manage patients who are discharged from the hospital with heart failure, to ensure that they are able to stabilize and manage their condition once they return home, and aren’t hospitalized again within a short time frame.
Readmissions. The SME recommends that the State conduct an analysis of children with readmissions to identify the factors that precipitated or likely led to readmission.
AutoNDA by SimpleDocs
Readmissions. Revenue lost due to readmissions at each facility during FY19 is shown in Table 6 below: If we reach our goals of 5% reduction in readmissions per year at each rural facility, we are able to calculate the cost savings below (Tables 7-10): Table 7: Grant Year 1 Expected Savings (5% readmission rate decrease) Year 1 Projected Total Readmissions Expected revenue lost per readmission Total Revenue Lost Easton 458 $1,961.00 $898,138.00 Dorchester 159 $1,470.00 $233,730.00 Chestertown 42 $2,088.00 $87,696.00 Easton 433 $1,961.00 $849,113.00 Dorchester 150 $1,470.00 $220,500.00 Chestertown 40 $2,088.00 $83,520.00 From the above cost-savings calculations, the combined revenue saved for each year of the grant is shown in Table 11. Table 11: Combined Cost Savings by Year Grant Year Averted Transfer Savings Surge Pool Savings Readmissions Savings Total for Year 1 $83,162.50 $8,551.83 $66,431.00 $158,145.33 2 166,325.00 $17,103.36 $136,911.00 $320,339.36 3 $249,487.50 $25,655.49 $203,342.00 $478,484.99 4 $332,650.00 $34,207.32 $270,264.00 $637,121.32 Based on this data, the project will reach sustainability by Year 2, and have a net benefit to UMMS and the UM Shore Regional system by year 3 and 4. Demonstrated financial success of the project with substantial net cost-savings at year 4 will demonstrate financial solvency to the University of Maryland Medical System and allow the hospital system to financially take control of the project after the award period.

Related to Readmissions

  • Nonadmission Nothing contained in this Agreement will be deemed or construed as an admission of wrongdoing or liability on the part of the Company.

  • Publications Neither Party shall publicly present or publish results of studies carried out under this Agreement (each such presentation or publication a “Publication”) without the opportunity for prior review by the other Party, except to the extent otherwise required by Applicable Law, in which case Section 12.3 shall apply with respect to disclosures required by the SEC and/or for regulatory filings. The submitting Party shall provide the other Party the opportunity to review any proposed Publication at least thirty (30) days prior to the earlier of its presentation or intended submission for publication. The submitting Party agrees, upon request by the other Party, not to submit or present any Publication until the other Party has had thirty (30) days to comment on any material in such Publication. The submitting Party shall consider the comments of the other Party in good faith, but will retain the sole authority to submit the manuscript for Publication; provided that the submitting Party agrees to delay such Publication as necessary to enable the Parties to file a Patent if such Publication might adversely affect such Patent. The submitting Party shall provide the other Party a copy of the Publication at the time of the submission or presentation. Notwithstanding the foregoing, BMS shall not have the right to publish or present Ambrx’s Confidential Information without Ambrx’s prior written consent, and Ambrx shall not have the right to publish or present BMS’ Confidential Information without BMS’ prior written consent. Each Party agrees to acknowledge the contributions of the other Party, and the employees of the other Party, in all publications as scientifically appropriate. This Section 12.4 shall not limit and shall be subject to Section 12.5. Nothing contained in this Section 12.4 shall prohibit the inclusion of information in a patent application claiming, and in furtherance of, the manufacture, use, sale or formulation of a Compound, provided that the non-filing Party is given a reasonable opportunity to review, comment upon and/or approve the information to be included prior to submission of such patent application, where and to the extent required by Article 9 hereof. Notwithstanding the foregoing, the Parties recognize that independent investigators have been engaged, and will be engaged in the future, to conduct Clinical Trials of Compounds and Products. The Parties recognize that such investigators operate in an academic environment and may release information regarding such studies in a manner consistent with academic standards; provided that each Party will use reasonable efforts to prevent publication prior to the filing of relevant patent applications and to ensure that no Confidential Information of either Party is disclosed.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!